Literature DB >> 11380224

Conformal re-irradiation of recurrent and new primary head-and-neck cancer.

L A Dawson1, L L Myers, C R Bradford, D B Chepeha, N D Hogikyan, T N Teknos, J E Terrell, G T Wolf, A Eisbruch.   

Abstract

PURPOSE: To review the outcome of head-and-neck cancer patients re-irradiated using conformal radiation. PATIENTS AND METHODS: From 1983 to 1999, 60 patients with recurrent or new primary head-and-neck cancer received re-irradiation at the University of Michigan. Twenty patients were excluded due to the planned cumulative radiation dose being less than 100 Gy (18) and absence of prior radiation details (2), leaving 40 patients. Thirty-five patients were re-irradiated for unresectable disease, while 4 patients received adjuvant re-irradiation for high-risk disease. Thirty-eight patients had recurrences from previously treated cancer (19 regional, 14 local, 5 regional and local), and 2 patients had new primary tumors. The median time from the first course of radiation to re-irradiation was 21 months. Thirty-one patients (78%) were re-irradiated with curative intent, whereas 9 were treated with palliative intent. Re-irradiation was delivered using conformal techniques in the majority of patients and with concurrent chemotherapy in 14 patients. The median re-irradiation dose was 60 Gy. The median cumulative dose received was 121 Gy. Five patients (13%) did not complete their prescribed course of re-irradiation.
RESULTS: The median survival following completion of re-irradiation was 12.5 months. The 1- and 2-year actuarial survival rates were 51.1% and 32.6%, respectively. On multivariate analysis, palliative intent of treatment, tumor bulk, and tumor site other than nasopharynx or larynx were associated with worse survival. The patients treated for unresectable disease did no worse than those treated adjuvantly. The median times to relapse-free survival, local-regional recurrence (LRR)-free survival, and ultimate LRR-free survival (allowing for surgical salvage) were 3.9 months, 7.8 months, and 8.7 months, respectively. Seven patients (18%) are presently alive with no evidence of disease, with a median follow-up of 49.9 months (range 3.3-78.9). Severe radiation-induced complications were seen in 7 patients (18%). Two other patients developed orocutaneous fistulas in the presence of tumor recurrence. Moderate fibrosis and trismus were common.
CONCLUSION: Despite the use of conformal techniques, the prognosis of patients treated with re-irradiation is poor, and complications are not infrequent. A subset of patients is salvageable, and high-dose re-irradiation should be considered in selected patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380224     DOI: 10.1016/s0360-3016(01)01456-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  Outcome after re-irradiation of head and neck cancer patients.

Authors:  Nele Platteaux; Piet Dirix; Bianca Vanstraelen; Sandra Nuyts
Journal:  Strahlenther Onkol       Date:  2010-12-22       Impact factor: 3.621

2.  The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.

Authors:  Jean-Claude M Rwigema; Dwight E Heron; Robert L Ferris; Regiane S Andrade; Michael K Gibson; Yong Yang; Cihat Ozhasoglu; Athanassios E Argiris; Jennifer R Grandis; Steven A Burton
Journal:  Am J Clin Oncol       Date:  2011-08       Impact factor: 2.339

3.  Reirradiation for recurrent head and neck cancer with salvage interstitial pulsed-dose-rate brachytherapy: Long-term results.

Authors:  Vratislav Strnad; Michael Lotter; Stephan Kreppner; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2015-01-10       Impact factor: 3.621

4.  Long-term outcome analysis after surgical salvage for recurrent tonsil carcinoma following radical radiotherapy.

Authors:  Gideon Y Bachar; Christopher Goh; David P Goldstein; Brian O'Sullivan; Jonathan C Irish
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-02       Impact factor: 2.503

5.  The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets.

Authors:  Aron Popovtzer; Iris Gluck; Douglas B Chepeha; Theodoros N Teknos; Jeffrey S Moyer; Mark E Prince; Carol R Bradford; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-01-08       Impact factor: 7.038

6.  A retrospective, deformable registration analysis of the impact of PET-CT planning on patterns of failure in stereotactic body radiation therapy for recurrent head and neck cancer.

Authors:  Kyle Wang; Dwight E Heron; John C Flickinger; Jean-Claude M Rwigema; Robert L Ferris; Gregory J Kubicek; James P Ohr; Annette E Quinn; Cihat Ozhasoglu; Barton F Branstetter
Journal:  Head Neck Oncol       Date:  2012-04-19

7.  Evaluation of Reirradiation in Locally Advanced Head and Neck Cancers: Toxicity and Early Clinical Outcomes.

Authors:  Amit Bahl; Arun Singh Oinam; Arun Elangovan; Satinder Kaur; Gaurav Trivedi; Roshan Verma; Sudhir Bhandari; Sushmita Ghoshal; Naresh Kumar Panda
Journal:  J Oncol       Date:  2018-03-26       Impact factor: 4.375

8.  A Systematic Review on Re-irradiation with Charged Particle Beam Therapy in the Management of Locally Recurrent Skull Base and Head and Neck Tumors.

Authors:  Mauricio E Gamez; Samir H Patel; Lisa A McGee; Terence T Sio; Mark McDonald; Jack Phan; Daniel J Ma; Robert L Foote; Jean-Claude M Rwigema
Journal:  Int J Part Ther       Date:  2021-06-25

9.  Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic.

Authors:  Kelly K Curtis; Helen J Ross; Ashley L Garrett; Theresa A Jizba; Ajay B Patel; Samir H Patel; William W Wong; Michele Y Halyard; Stephen J Ko; Heidi E Kosiorek; Robert L Foote
Journal:  Radiat Oncol       Date:  2016-04-09       Impact factor: 3.481

10.  Local Tumor Control and Normal Tissue Toxicity of Pulsed Low-Dose Rate Radiotherapy for Recurrent Lung Cancer: An In Vivo Animal Study.

Authors:  Peng Zhang; Bin Wang; Xiaoming Chen; Dusica Cvetkovic; Lili Chen; Jinyi Lang; C-M Ma
Journal:  Dose Response       Date:  2015-05-25       Impact factor: 2.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.